On May 20, 2026, local time, Hospitalar 2026 — Latin America’s premier healthcare event — officially opened at the São Paulo Expo in São Paulo, Brazil. As the largest and most specialized medical‑industry trade show in Latin America, the event brought together over a thousand global healthcare companies, showcasing cutting-edge technologies and innovative products across the entire medical value chain. It serves as a key platform for businesses to tap into the Latin American market and foster international collaboration. Nanjing Shuangwei Biotechnology Co., Ltd., a nationally recognized “Specialized, Refined, Distinctive and Innovative” small giant enterprise, made a striking debut with its two core product lines—safe blood transfusion and advanced wound care. On the first day of the exhibition, the company drew significant attention, emerging as a standout Chinese brand thanks to its high‑quality offerings and robust technological expertise.

With more than two decades of dedicated expertise in the medical device sector, Shuangwei Biotechnology is a pioneer in China’s blood filtration and transfusion equipment field, focusing on independent R&D and technological innovation in the areas of blood safety and trauma repair. The company holds over one hundred core technologies, with product quality aligned to international standards; several of its technologies have achieved import substitution, and its products are used in numerous top-tier hospitals across China while exported to more than thirty countries and regions worldwide. This participation in the Hospitalar trade show in Brazil marks an important step in Shuangwei Biotechnology’s global expansion strategy for 2026. By leveraging Brazil as a key market, the company aims to extend its reach throughout Latin America, further broadening its overseas footprint and showcasing the robust capabilities of China’s advanced medical manufacturing on the international stage.

On the first day of the exhibition, Shuangwei Biotechnology’s booth attracted a large number of procurement personnel from medical institutions, industry distributors and professional visitors who stopped by for discussions. In response to pressing clinical needs in Latin America, the company showcased a range of flagship products, including its blood filtration series, PRP preparation systems, portable negative-pressure drainage devices, and fiberglass casting tape. Among these, the blood filtration product—featuring proprietary membrane technology—effectively purifies blood and reduces adverse reactions during transfusions, meeting the safety‑focused transfusion care requirements of hospitals across all levels in the region. Meanwhile, the lightweight negative-pressure wound therapy device is precisely tailored to local scenarios involving trauma, burns, and postoperative recovery. With its outstanding advantages including high cost effectiveness, robust stability, and ease of maintenance, it addresses the pain points of imported equipment—high costs and complex operations—and has earned widespread recognition from attendees.

At this exhibition, Shuangwei Biotechnology assembled a dedicated on-site international trade team to provide visitors with one‑on‑one product demonstrations, technical briefings, and customized solution design services. Drawing on the unique characteristics of Brazil’s and broader Latin American healthcare systems and addressing key clinical challenges, the team offered tailored responses to critical questions regarding product registration, clinical applications, and regional distribution, earning unanimous praise for its efficient and professional service. On the first day of the event, the company secured preliminary cooperation agreements with numerous Brazilian local distributors and healthcare institutions from neighboring Latin American countries, marking fruitful market outreach progress.

The exhibition is still ongoing, and Shuangwei Biotechnology will continue to conduct on-site discussions, strengthen connections with prospective clients, and steadily advance its channel development strategy across the Latin American market. Looking ahead, Shuangwei Biotechnology will remain focused on pursuing core technological innovation, refining its product portfolio and overseas service network, and leveraging Brazil as a strategic hub to deepen its presence in Latin America. The company will continue to deliver high‑quality “Shuangwei‑Made” products, expand international collaborations in the healthcare sector, and support the advancement of global clinical care.